{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T23:52:25Z","timestamp":1773532345903,"version":"3.50.1"},"reference-count":204,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.blre.2023.101130","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T20:42:22Z","timestamp":1693341742000},"page":"101130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution"],"prefix":"10.1016","volume":"62","author":[{"given":"Enrico","family":"Santinelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Rosaria","family":"Pascale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoer","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talha","family":"Badar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian F.","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan P.","family":"Bewersdorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Gurnari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2023.101130_bb0005","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ijc.2910220105","article-title":"Chromosome 14 translocations in non-Burkitt lymphomas","volume":"22","author":"Fukuhara","year":"1978","journal-title":"Int J Cancer"},{"key":"10.1016\/j.blre.2023.101130_bb0010","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2003-07-2469","article-title":"VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia","volume":"103","author":"Egle","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0015","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/335440a0","article-title":"Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells","volume":"335","author":"Vaux","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.blre.2023.101130_bb0020","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1182\/blood.V81.11.3091.3091","article-title":"High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy","volume":"81","author":"Campos","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0025","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/blood.V84.2.595.595","article-title":"Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells","volume":"84","author":"Campos","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0030","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.blre.2023.101130_bb0035","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1182\/blood-2004-07-2761","article-title":"Apoptosis-based therapies for hematologic malignancies","volume":"106","author":"Reed","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0040","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.blre.2023.101130_bb0045","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1038\/sj.onc.1209608","article-title":"Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy","volume":"25","author":"Fulda","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.blre.2023.101130_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2014.00197","article-title":"X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy","volume":"4","author":"Obexer","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2023.101130_bb0055","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41419-019-1407-6","article-title":"BCL-2 family isoforms in apoptosis and cancer","volume":"10","author":"Warren","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.blre.2023.101130_bb0060","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy","volume":"15","author":"Czabotar","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.blre.2023.101130_bb0065","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/cdd.2015.50","article-title":"The BCL-2 protein family, BH3-mimetics and cancer therapy","volume":"22","author":"Delbridge","year":"2015","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.blre.2023.101130_bb0070","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4161\/cbt.4.2.1508","article-title":"Overview of cell death signaling pathways","volume":"4","author":"Jin","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.blre.2023.101130_bb0075","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1126\/science.1099320","article-title":"The pathophysiology of mitochondrial cell death","volume":"305","author":"Green","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.blre.2023.101130_bb0080","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/348334a0","article-title":"Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death","volume":"348","author":"Hockenbery","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.blre.2023.101130_bb0085","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.molcel.2010.01.025","article-title":"The BCL-2 family reunion","volume":"37","author":"Chipuk","year":"2010","journal-title":"Mol Cell"},{"key":"10.1016\/j.blre.2023.101130_bb0090","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1126\/science.1059108","article-title":"Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death","volume":"292","author":"Wei","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.blre.2023.101130_bb0095","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.bbamcr.2010.11.024","article-title":"BH3-only proteins: orchestrators of apoptosis","volume":"1813","author":"Shamas-Din","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.blre.2023.101130_bb0100","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrc2072","article-title":"The p53 family in differentiation and tumorigenesis","volume":"7","author":"Stiewe","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.blre.2023.101130_bb0105","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrc3430","article-title":"MDM2, MDMX and p53 in oncogenesis and cancer therapy","volume":"13","author":"Wade","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.blre.2023.101130_bb0110","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41419-021-03902-6","article-title":"Puma, noxa, p53, and p63 differentially mediate stress pathway induced apoptosis","volume":"12","author":"Wang","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.blre.2023.101130_bb0115","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11010-020-03874-9","article-title":"Crosstalk between Noxa, Bcl-2, and ceramide in mediating p53-dependent apoptosis in Molt-4 human T-cell leukemia","volume":"475","author":"Kobeissy","year":"2020","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.blre.2023.101130_bb0120","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1182\/blood-2017-02-763086","article-title":"Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy","volume":"130","author":"Prokocimer","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0125","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF03402141","article-title":"Mdm2: the ups and downs","volume":"5","author":"Juven-Gershon","year":"1999","journal-title":"Mol Med"},{"key":"10.1016\/j.blre.2023.101130_bb0130","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s000180050273","article-title":"Functions of the MDM2 oncoprotein","volume":"55","author":"Freedman","year":"1999","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.blre.2023.101130_bb0135","doi-asserted-by":"crossref","first-page":"36031","DOI":"10.1074\/jbc.274.51.36031","article-title":"Regulation of the p53 tumor suppressor protein","volume":"274","author":"Oren","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2023.101130_bb0140","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrm3919","article-title":"Protein neddylation: beyond cullin-RING ligases","volume":"16","author":"Enchev","year":"2015","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.blre.2023.101130_bb0145","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13008-016-0022-5","article-title":"Cullin-RING ligases in regulation of autophagy","volume":"11","author":"Cui","year":"2016","journal-title":"Cell Div"},{"key":"10.1016\/j.blre.2023.101130_bb0150","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cellsig.2018.01.009","article-title":"Protein neddylation and its alterations in human cancers for targeted therapy","volume":"44","author":"Zhou","year":"2018","journal-title":"Cell Signal"},{"key":"10.1016\/j.blre.2023.101130_bb0155","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12943-019-0979-1","article-title":"Neddylation: a novel modulator of the tumor microenvironment","volume":"18","author":"Zhou","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.blre.2023.101130_bb0160","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ccr.2011.01.002","article-title":"NEDD8 pathways in cancer, Sine Quibus Non","volume":"19","author":"Watson","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2023.101130_bb0165","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101130_bb0170","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0175","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/sj.thj.6200245","article-title":"Effect of bcl-2 antisense oligodeoxynucleotides on drug sensitivity of leukemic cells","volume":"4","author":"Zhang","year":"2003","journal-title":"Hematol J"},{"key":"10.1016\/j.blre.2023.101130_bb0180","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1182\/blood-2002-06-1899","article-title":"Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia","volume":"101","author":"Marcucci","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0185","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1200\/JCO.2005.09.118","article-title":"Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity","volume":"23","author":"Marcucci","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101130_bb0190","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1182\/bloodadvances.2021004233","article-title":"Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)","volume":"5","author":"Walker","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101130_bb0195","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1021\/jm0507532","article-title":"Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis","volume":"49","author":"Petros","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.blre.2023.101130_bb0200","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.clml.2014.04.007","article-title":"A phase II, multicenter, open-label study of obatoclax mesylate in patients with previously untreated myelodysplastic syndromes with anemia or thrombocytopenia","volume":"14","author":"Arellano","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2023.101130_bb0205","doi-asserted-by":"crossref","first-page":"8295","DOI":"10.1158\/1078-0432.CCR-08-0999","article-title":"A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies","volume":"14","author":"Schimmer","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2023.101130_bb0210","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2023.101130_bb0215","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2023.101130_bb0220","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2023.101130_bb0225","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00277-012-1537-8","article-title":"Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells","volume":"91","author":"Tsao","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2023.101130_bb0230","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101130_bb0235","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0240","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2023.101130_bb0245","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.20.00572","article-title":"Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy","volume":"38","author":"Chua","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101130_bb0250","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101130_bb0255","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","article-title":"Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial","volume":"8","author":"Kadia","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2023.101130_bb0260","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101130_bb0265","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2023.101130_bb0270","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2023.101130_bb0275","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2022-157210","article-title":"Updated results from a phase I\/II study of the triplet combination of azacitidine, venetoclax and gilteritinib for patients with FLT3 -mutated acute myeloid leukemia","volume":"140","author":"Short","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0280","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2016-10-745133","article-title":"Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor","volume":"129","author":"Lee","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0285","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101130_bb0290","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1182\/blood.V128.22.2830.2830","article-title":"Gilteritinib (ASP2215), a novel FLT3\/AXL inhibitor: preclinical evaluation in combination with azacitidine in acute myeloid leukemia","volume":"128","author":"Ueno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0295","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1080\/10428194.2022.2062345","article-title":"A multi-arm phase Ib\/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed\/refractory acute myeloid leukemia","volume":"63","author":"Short","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2023.101130_bb0300","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1182\/blood-2011-02-337261","article-title":"Applicability of a \u2018pick a winner\u2019 trial design to acute myeloid leukemia","volume":"118","author":"Hills","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0305","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2010-03-275446","article-title":"Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia","volume":"116","author":"Zhou","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0310","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","article-title":"Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia","volume":"117","author":"Zhou","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0315","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/sj.leu.2404720","article-title":"CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease","volume":"21","author":"Fevery","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2023.101130_bb0320","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood-2009-03-206672","article-title":"PD-1\/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model","volume":"114","author":"Zhang","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0325","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2023.101130_bb0330","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.V128.22.763.763","article-title":"Phase IB\/II study of nivolumab in combination with azacytidine (AZA) in patients (pts) with relapsed acute myeloid leukemia (AML)","volume":"128","author":"Daver","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0335","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2023.101130_bb0340","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41375-018-0070-8","article-title":"Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes","volume":"32","author":"Daver","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2023.101130_bb0345","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/2159-8290.CD-19-0759","article-title":"Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade","volume":"11","author":"Kohlhapp","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2023.101130_bb0350","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2023.101130_bb0355","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s12185-020-03023-4","article-title":"Clinical outcomes of gemtuzumab ozogamicin for relapsed acute myeloid leukemia: single-institution experience","volume":"113","author":"Hosono","year":"2021","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2023.101130_bb0360","article-title":"Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: multi-center real life data from Turkey","volume":"16","author":"K\u00fc\u00e7\u00fckdiler","year":"2021","journal-title":"Leuk Res Rep"},{"key":"10.1016\/j.blre.2023.101130_bb0365","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.htct.2020.07.008","article-title":"Gemtuzumab ozogamicin is efficacious in attaining complete remission in relapsed\/refractory acute leukemia prior to hematopoietic cell transplant: a case series","volume":"43","author":"Fatobene","year":"2021","journal-title":"Hematol Transfus Cell Ther"},{"key":"10.1016\/j.blre.2023.101130_bb0370","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00277-021-04471-6","article-title":"Glasdegib in combination with low-dose cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients","volume":"100","author":"Zucenka","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2023.101130_bb0375","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/cncr.31896","article-title":"The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia","volume":"125","author":"Williams","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2023.101130_bb0380","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1158\/1078-0432.CCR-21-0845","article-title":"A phase I, open-label, dose-escalation study of the OX40 agonist ivuxolimab in patients with locally advanced or metastatic cancers","volume":"28","author":"Diab","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2023.101130_bb0385","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1158\/0008-5472.CAN-16-1793","article-title":"Preclinical characterization of BET family bromodomain inhibitor ABBV-075 suggests combination therapeutic strategies","volume":"77","author":"Bui","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2023.101130_bb0390","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.blre.2023.101130_bb0395","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1002\/cncr.33590","article-title":"A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed\/refractory acute myeloid leukemia","volume":"127","author":"Borthakur","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2023.101130_bb0400","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1182\/blood-2022-169509","article-title":"ELN risk stratification is not predictive of outcomes for treatment-Na\u00efve patients with acute myeloid leukemia treated with venetoclax and azacitidine","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0405","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood.2022016963","article-title":"Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0410","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2217\/fon-2017-0523","article-title":"The role of IDH mutations in acute myeloid leukemia","volume":"14","author":"Montalban-Bravo","year":"2018","journal-title":"Future Oncol"},{"key":"10.1016\/j.blre.2023.101130_bb0415","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1182\/blood-2018-99-119688","article-title":"Combination of enasidenib and venetoclax shows superior anti-leukemic activity against IDH2 mutated AML in patient-derived xenograft models","volume":"132","author":"Cathelin","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0420","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-021-00604-2","article-title":"Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy","volume":"12","author":"Venugopal","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2023.101130_bb0425","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.1016\/S2152-2650(21)01798-5","article-title":"MDS-158: updated safety and efficacy of venetoclax in combination with azacitidine for the treatment of patients with treatment-Na\u00efve, higher-risk myelodysplastic syndromes: phase 1b results","volume":"21","author":"Wei","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2023.101130_bb0430","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1182\/bloodadvances.2020001482","article-title":"Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure","volume":"4","author":"Ball","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101130_bb0435","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS7054","article-title":"Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-na\u00efve higher-risk myelodysplastic syndromes","volume":"39","author":"Zeidan","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101130_bb0440","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ajh.26771","article-title":"A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes","volume":"98","author":"Zeidan","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2023.101130_bb0445","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41375-021-01240-2","article-title":"Activity of venetoclax-based therapy in chronic myelomonocytic leukemia","volume":"35","author":"Montalban-Bravo","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2023.101130_bb0450","doi-asserted-by":"crossref","first-page":"e756","DOI":"10.1016\/S2352-3026(22)00216-2","article-title":"Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study","volume":"9","author":"Bazinet","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2023.101130_bb0455","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1159\/000506346","article-title":"Venetoclax and BCR-ABL tyrosine kinase inhibitor combinations: outcome in patients with Philadelphia chromosome-positive advanced myeloid leukemias","volume":"143","author":"Maiti","year":"2020","journal-title":"Acta Haematol"},{"key":"10.1016\/j.blre.2023.101130_bb0460","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood-2022-170773","article-title":"A phase II study of the combination of decitabine, venetoclax and ponatinib in patients with chronic myeloid leukemia (CML) in myeloid blast phase (MBP) or Philadelphia-chromosome positive (Ph+) acute myeloid leukemia (AML)","volume":"140","author":"Senapati","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0465","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2023.101130_bb0470","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1182\/blood-2011-04-347849","article-title":"Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets","volume":"118","author":"Schoenwaelder","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0475","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1200\/JCO.21.02188","article-title":"Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy","volume":"40","author":"Harrison","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101130_bb0480","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1756-8722-5-2","article-title":"Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in essential thrombocythemia and myelofibrosis","volume":"5","author":"Tognon","year":"2012","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2023.101130_bb0485","article-title":"JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL","volume":"10","author":"Guo","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.blre.2023.101130_bb0490","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/01.HS9.0000843680.94912.c5","article-title":"S197: navitoclax plus ruxolitinib in JAK inhibitor-Na\u00efve patients with myelofibrosis: preliminary safety and efficacy in a multicenter, open-label phase 2 study","volume":"6","author":"Passamonti","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.blre.2023.101130_bb0495","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13045-020-00928-9","article-title":"DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas","volume":"13","author":"He","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2023.101130_bb0500","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.blre.2023.101130_bb0505","doi-asserted-by":"crossref","first-page":"27696","DOI":"10.1038\/srep27696","article-title":"Targeting MCL-1\/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia","volume":"6","author":"Lin","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.blre.2023.101130_bb0510","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1182\/blood.V91.3.991","article-title":"Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse","volume":"91","author":"Kaufmann","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0515","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2023.101130_bb0520","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2023.101130_bb0525","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","article-title":"AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells","volume":"26","author":"Cidado","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2023.101130_bb0530","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41375-018-0261-3","article-title":"Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia","volume":"33","author":"Moujalled","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2023.101130_bb0535","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia","volume":"8","author":"Ramsey","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2023.101130_bb0540","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3324\/haematol.2020.260331","article-title":"Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition","volume":"107","author":"Carter","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2023.101130_bb0545","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood.2021014241","article-title":"Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1","volume":"140","author":"Janssen","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0550","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1101\/gad.215855.113","article-title":"Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction","volume":"27","author":"Wang","year":"2013","journal-title":"Genes Dev"},{"key":"10.1016\/j.blre.2023.101130_bb0555","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","article-title":"Targeting MCL-1 in cancer: current status and perspectives","volume":"14","author":"Wang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2023.101130_bb0560","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1158\/1078-0432.CCR-07-0381","article-title":"Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia","volume":"13","author":"Karp","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2023.101130_bb0565","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.leukres.2009.11.007","article-title":"Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia","volume":"34","author":"Karp","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2023.101130_bb0570","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3324\/haematol.2015.125849","article-title":"Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine\/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia","volume":"100","author":"Zeidner","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2023.101130_bb0575","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.leukres.2018.08.005","article-title":"Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7+3) in newly diagnosed high-risk acute myeloid leukemia (AML)","volume":"72","author":"Zeidner","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2023.101130_bb0580","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1158\/1078-0432.CCR-20-2649","article-title":"Phase I study of alvocidib followed by 7+3 (cytarabine + daunorubicin) in newly diagnosed acute myeloid leukemia","volume":"27","author":"Zeidner","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2023.101130_bb0585","doi-asserted-by":"crossref","first-page":"107206","DOI":"10.18632\/oncotarget.22284","article-title":"Combined venetoclax and alvocidib in acute myeloid leukemia","volume":"8","author":"Bogenberger","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2023.101130_bb0590","doi-asserted-by":"crossref","DOI":"10.1002\/hon.3159","article-title":"A phase 1b study of venetoclax and alvocidib in patients with relapsed\/refractory acute myeloid leukemia","author":"Jonas","year":"2023","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.blre.2023.101130_bb0595","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1158\/1078-0432.CCR-12-2926","article-title":"A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2","volume":"19","author":"Holkova","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2023.101130_bb0605","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41408-023-00830-w","article-title":"Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics","volume":"13","author":"Carter","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2023.101130_bb0610","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.blre.2023.101130_bb0615","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/JCO.2010.30.2554","article-title":"Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications","volume":"29","author":"Marcucci","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101130_bb0620","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026336","article-title":"The role of MDM2 amplification and overexpression in tumorigenesis","volume":"6","author":"Oliner","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.blre.2023.101130_bb0625","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/358080a0","article-title":"Amplification of a gene encoding a p53-associated protein in human sarcomas","volume":"358","author":"Oliner","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.blre.2023.101130_bb0630","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026211","article-title":"Attenuating the p53 pathway in human cancers: many means to the same end","volume":"6","author":"Wasylishen","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.blre.2023.101130_bb0635","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2010-01-261628","article-title":"Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia","volume":"116","author":"Long","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0640","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1158\/1535-7163.MCT-15-0429","article-title":"Inhibition of wild-type p53-expressing AML by the novel small molecule HDM2 inhibitor CGM097","volume":"14","author":"Weisberg","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.blre.2023.101130_bb0645","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.blre.2023.101130_bb0650","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/blood.V122.21.498.498","article-title":"Phase 1b study of the MDM2 antagonist RG7112 in combination with 2 doses\/schedules of cytarabine","volume":"122","author":"Yee","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0655","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1078-0432.CCR-15-0481","article-title":"Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia","volume":"22","author":"Andreeff","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2023.101130_bb0660","doi-asserted-by":"crossref","first-page":"31980","DOI":"10.18632\/oncotarget.7881","article-title":"P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis","volume":"7","author":"Mahfoudhi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2023.101130_bb0665","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.1021\/jm400487c","article-title":"Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development","volume":"56","author":"Ding","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.blre.2023.101130_bb0670","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1182\/blood.V124.21.116.116","article-title":"Phase 1\/1b study of RG7388, a potent MDM2 antagonist, in acute myelogenous leukemia (AML) patients (Pts)","volume":"124","author":"Yee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0675","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1182\/blood.V128.22.2843.2843","article-title":"Minimal residual disease (MRD) assessment by multiparametric flow cytometry is prognostic for progression-free survival in phase 1\/1b relapsed\/refractory acute myeloid leukemia (AML) patients treated with idasanutlin MDM2 antagonist","volume":"128","author":"Lanza","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0680","first-page":"4147","article-title":"Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial","volume":"6","author":"Konopleva","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101130_bb0685","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41375-020-0949-z","article-title":"MDM2 inhibition: an important step forward in cancer therapy","volume":"34","author":"Konopleva","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2023.101130_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113425","article-title":"Development of MDM2 degraders based on ligands derived from Ugi reactions: lessons and discoveries","volume":"219","author":"Wang","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.blre.2023.101130_bb0695","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1200\/JCO.2009.21.8172","article-title":"Phase I\/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia","volume":"27","author":"Schimmer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101130_bb0700","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.clml.2011.03.033","article-title":"Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study","volume":"11","author":"Schimmer","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2023.101130_bb0705","doi-asserted-by":"crossref","first-page":"djt440","DOI":"10.1093\/jnci\/djt440","article-title":"Synergistic targeting of AML stem\/progenitor cells with IAP antagonist birinapant and demethylating agents","volume":"106","author":"Carter","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.blre.2023.101130_bb0710","doi-asserted-by":"crossref","first-page":"7060","DOI":"10.1200\/JCO.2016.34.15_suppl.7060","article-title":"A phase 2 study of azacitidine (5-AZA) with or without birinapant in subjects with higher risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML)","volume":"34","author":"Donnellan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101130_bb0715","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-019-0157-6","article-title":"The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells","volume":"9","author":"Craver","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.blre.2023.101130_bb0720","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1182\/blood-2009-11-254862","article-title":"Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia","volume":"115","author":"Swords","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0725","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood-2010-03-272567","article-title":"MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma","volume":"116","author":"Milhollen","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0730","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1182\/blood.V116.21.2988.2988","article-title":"MLN4924, a novel investigational NEDD8 activating enzyme inhibitor, exhibits preclinical activity in multiple myeloma and Waldenstr\u00f6m\u2019s macroglobulinemia through mechanism distinct from existing proteasome inhibitors","volume":"116","author":"McMillin","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0735","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1182\/blood.V118.21.1414.1414","article-title":"Investigational NEDD8-activating enzyme (NAE) inhibitor, MLN4924, demonstrates activity against primary AML blast, progenitor and stem cell populations","volume":"118","author":"Sen","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0740","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1182\/blood.V116.21.658.658","article-title":"The novel, investigational NEDD8-activating enzyme inhibitor MLN4924 in adult patients with acute myeloid leukemia (AML) or high-grade myelodysplastic syndromes (MDS): a phase 1 study","volume":"116","author":"Swords","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0745","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0750","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/s41375-021-01125-4","article-title":"Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS\/CMML or low-blast AML","volume":"35","author":"Sekeres","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2023.101130_bb0755","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1182\/bloodadvances.2022007334","article-title":"Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML","volume":"6","author":"Ad\u00e8s","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101130_bb0760","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.blre.2023.101130_bb0765","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1200\/JCO.2015.62.7273","volume":"33","author":"Devine","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101130_bb0770","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101130_bb0775","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.bbmt.2015.10.024","article-title":"Myeloablative, but not reduced-intensity, conditioning overcomes the negative effect of flow-cytometric evidence of leukemia in acute myeloid leukemia","volume":"22","author":"Ustun","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101130_bb0780","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1182\/bloodadvances.2021005566","article-title":"Adding venetoclax to fludarabine\/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active","volume":"5","author":"Garcia","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101130_bb0785","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/blood.2022016082","article-title":"Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1\/2 upregulation","volume":"140","author":"Ho","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0790","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and mechanisms of venetoclax resistance","volume":"58","author":"Bose","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2023.101130_bb0795","doi-asserted-by":"crossref","first-page":"380","DOI":"10.20517\/cdr.2021.125","article-title":"Venetoclax resistance: mechanistic insights and future strategies","volume":"5","author":"Ong","year":"2022","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.blre.2023.101130_bb0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.101036","article-title":"Acute myeloid leukemia resistant to venetoclax-based therapy: what does the future hold?","volume":"59","author":"Dhakal","year":"2023","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2023.101130_bb0815","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2023.101130_bb0820","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41392-021-00578-4","article-title":"FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3\/ITD acute leukemia cells through BIM activation","volume":"6","author":"Zhu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.blre.2023.101130_bb0825","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","article-title":"Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia","volume":"25","author":"Ma","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2023.101130_bb0830","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1182\/blood-2008-12-196055","article-title":"FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation","volume":"114","author":"Yoshimoto","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0835","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1038\/sj.onc.1202796","article-title":"IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line","volume":"18","author":"Dumon","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.blre.2023.101130_bb0840","doi-asserted-by":"crossref","first-page":"E202","DOI":"10.1002\/ajh.25146","article-title":"Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia","volume":"93","author":"Chyla","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2023.101130_bb0845","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-142687","article-title":"Quizartinib with decitabine +\/- venetoclax is highly active in patients (pts) with FLT3 -ITD mutated (Mut) acute myeloid leukemia (AML): clinical report and signaling cytof profiling from a phase IB\/II trial","volume":"136","author":"Yilmaz","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0850","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","article-title":"Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia","volume":"1","author":"Zhang","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.blre.2023.101130_bb0855","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1186\/s12935-020-01614-z","article-title":"Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies","volume":"20","author":"Yue","year":"2020","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.blre.2023.101130_bb0860","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3324\/haematol.2020.252569","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens","volume":"106","author":"Maiti","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2023.101130_bb0865","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0870","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1159\/000525566","article-title":"A phase II study of azacitidine, venetoclax, and trametinib in relapsed or refractory acute myeloid leukemia harboring RAS pathway-activating mutations","volume":"145","author":"Desikan","year":"2022","journal-title":"Acta Haematol"},{"key":"10.1016\/j.blre.2023.101130_bb0875","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1080\/17474086.2020.1852923","article-title":"Apoptosis targeted therapies in acute myeloid leukemia: an update","volume":"13","author":"Ball","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2023.101130_bb0880","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2023.101130_bb0885","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/cncr.33689","article-title":"Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax","volume":"127","author":"Kim","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2023.101130_bb0890","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1111\/bjh.16166","article-title":"Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia","volume":"187","author":"Aldoss","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101130_bb0895","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood.2020010167","article-title":"Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias","volume":"137","author":"Thijssen","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0900","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41419-018-0463-7","article-title":"APR-246 reactivates mutant p53 by targeting cysteines 124 and 277","volume":"9","author":"Zhang","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.blre.2023.101130_bb0905","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3324\/haematol.2020.259531","article-title":"APR-246 induces early cell death by ferroptosis in acute myeloid leukemia","volume":"107","author":"Birsen","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2023.101130_bb0910","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101130_bb0915","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des My\u00e9lodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101130_bb0920","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S2352-3026(22)00403-3","article-title":"Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study","volume":"10","author":"Garcia-Manero","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2023.101130_bb0925","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.22.00181","article-title":"Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes","volume":"40","author":"Mishra","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101130_bb0930","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3389\/fonc.2019.01380","article-title":"Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies","volume":"9","author":"Chao","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2023.101130_bb0935","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2020-140528","article-title":"Pre-clinical combination of AO-176, a highly differentiated clinical stage CD47 antibody, with either azacitidine or venetoclax significantly enhances DAMP induction and phagocytosis of acute myeloid leukemia","volume":"136","author":"Donio","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0940","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2019-126271","article-title":"The first-in-class anti-CD47 antibody magrolimab (5F9) in combination with azacitidine is effective in MDS and AML patients: ongoing phase 1b results","volume":"134","author":"Sallman","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0945","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2021-153638","article-title":"Phase I\/II study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (Magro) in patients (pts) with newly diagnosed older\/unfit or high-risk acute myeloid leukemia (AML) and relapsed\/refractory (R\/R) AML","volume":"138","author":"Daver","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0950","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.blre.2023.101130_bb0955","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","article-title":"Inhibition of amino acid metabolism selectively targets human leukemia stem cells","volume":"34","author":"Jones","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2023.101130_bb0960","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2023.101130_bb0965","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies","volume":"36","author":"Gui\u00e8ze","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2023.101130_bb0970","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.stem.2020.07.021","article-title":"Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells","volume":"27","author":"Jones","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.blre.2023.101130_bb0975","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","article-title":"Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells","volume":"1","author":"Stevens","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.blre.2023.101130_bb0980","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood-2015-12-687814","article-title":"High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells","volume":"128","author":"Oppermann","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb0985","doi-asserted-by":"crossref","first-page":"21166","DOI":"10.18632\/oncotarget.24989","article-title":"Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells","volume":"9","author":"Chukkapalli","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2023.101130_bb0990","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/imm.12665","article-title":"Functional exhaustion of CD4+ T cells induced by co-stimulatory signals from myeloid leukaemia cells","volume":"149","author":"Ozkazanc","year":"2016","journal-title":"Immunology"},{"key":"10.1016\/j.blre.2023.101130_bb0995","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1182\/blood-2006-07-035519","article-title":"Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors","volume":"109","author":"Epling-Burnette","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101130_bb1000","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/ijc.25791","article-title":"Elevated frequencies of CD4+ CD25+ CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia","volume":"129","author":"Shenghui","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.blre.2023.101130_bb1005","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1186\/s12885-020-06961-8","article-title":"Hyperfunction of CD4 CD25 regulatory T cells in de novo acute myeloid leukemia","volume":"20","author":"Wan","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.blre.2023.101130_bb1010","article-title":"PD-1 and TIGIT are highly co-expressed on CD8+ T cells in AML patient bone marrow","volume":"11","author":"Xu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2023.101130_bb1015","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.stem.2015.07.011","article-title":"A TIM-3\/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression","volume":"17","author":"Kikushige","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.blre.2023.101130_bb1020","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-020-00853-x","article-title":"Expression patterns of immune checkpoints in acute myeloid leukemia","volume":"13","author":"Chen","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2023.101130_bb1025","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.3389\/fonc.2020.01595","article-title":"Overexpression of TIGIT in NK and T cells contributes to tumor immune escape in myelodysplastic syndromes","volume":"10","author":"Meng","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2023.101130_bb1035","doi-asserted-by":"crossref","DOI":"10.3390\/cells11142249","article-title":"Immune checkpoint inhibition in acute myeloid leukemia and myelodysplastic syndromes","volume":"11","author":"Abaza","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.blre.2023.101130_bb1040","doi-asserted-by":"crossref","first-page":"S255","DOI":"10.1016\/S2152-2650(22)01303-9","article-title":"AML-484 first results of a phase II study (STIMULUS-AML1) investigating sabatolimab + azacitidine + venetoclax in patients with newly diagnosed acute myeloid leukemia (ND AML)","volume":"22","author":"Zeidan","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:31:04Z","timestamp":1759437064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X23000917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":204,"alternative-id":["S0268960X23000917"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101130","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101130","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101130"}}